Publication | Closed Access

Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage

Drug TargetingVivo PassageTarget-specific BindingPolymer-drug ConjugateMedicineLiposomal DoxorubicinTumor TargetingAnti-cancer AgentPharmacologyCell BiologyDrug Discovery